The addition of docetaxel to standard therapy clinically and significantly improved survival for men with locally advanced or metastatic hormone-naive prostate cancer, according to findings from the STAMPEDE trial.However, the addition of zoledronic acid to standard therapy was not associated with improved survival, results showed.
No comments:
Post a Comment